Evolve Biologics
Evolve Biologics is an innovative biologics company dedicated to advancing plasma-derived therapeutics through proprietary technology PlasmaCap EBA®. The company aims to deliver higher purity, efficiency, and reliability in plasma protein extraction, improving lives for people with rare diseases. With a focus on innovation, quality, and sustainability, Evolve is building a broad product portfolio and a state-of-the-art manufacturing facility in Sachse, Texas, to meet the growing global demand for plasma-derived therapies.
Industries
Nr. of Employees
small (1-50)
Evolve Biologics
4-2855 Argentia Road, Mississauga, Ontario, Canada L5N 8G6
Patents
Products
Intravenous immunoglobulin (IVIG) candidate
An IVIG product candidate manufactured using a chromatography-based purification process; completed adult and pediatric Phase III clinical trials and being advanced toward regulatory submission.
Human serum albumin candidate
Albumin product candidate developed using the chromatography-based purification approach, in clinical development with a planned regulatory submission timeframe.
Alpha-1 antitrypsin (AAT) - evaluated as future candidate
Alpha-1 antitrypsin identified for potential future development using chromatography-based purification; currently under assessment.
Intravenous immunoglobulin (IVIG) candidate
An IVIG product candidate manufactured using a chromatography-based purification process; completed adult and pediatric Phase III clinical trials and being advanced toward regulatory submission.
Human serum albumin candidate
Albumin product candidate developed using the chromatography-based purification approach, in clinical development with a planned regulatory submission timeframe.
Alpha-1 antitrypsin (AAT) - evaluated as future candidate
Alpha-1 antitrypsin identified for potential future development using chromatography-based purification; currently under assessment.
Services
On-site production using a chromatography-based purification process in a purpose-built commercial facility designed to process up to one million liters annually with planned expansion.
Design and conduct of multicenter clinical trials including safety, tolerability, and pharmacokinetic assessments; clinical trial inquiries managed via a Clinical Affairs contact.
On-site production using a chromatography-based purification process in a purpose-built commercial facility designed to process up to one million liters annually with planned expansion.
Design and conduct of multicenter clinical trials including safety, tolerability, and pharmacokinetic assessments; clinical trial inquiries managed via a Clinical Affairs contact.
Expertise Areas
- Chromatography-based purification and process development
- Plasma-derived therapeutics development (IVIG, albumin, AAT)
- Clinical trial management and execution (multicenter Phase III)
- Bioprocess scale-up and commercial manufacturing
Key Technologies
- Expanded-bed chromatography
- Adsorbent bead-based affinity chromatography
- Chromatography column sequencing and fluidization systems
- Alternative plasma fractionation to cold-ethanol methods
News & Updates
Evolve Biologics announced the appointment of Chris Carr as Chief Financial Officer, responsible for finance and accounting functions.
Evolve Biologics announced the site selection, land purchase, and groundbreaking ceremony for its first manufacturing facility in Sachse, Texas, which will use PlasmaCap EBA® technology.
Evolve announced the selection of DPR Construction as the general contractor for its first manufacturing facility in Texas, which will utilize PlasmaCap EBA® technology.
Evolve announced the successful completion of Phase III clinical trials for PlasmaCap IG, an intravenous immunoglobulin therapy for primary immune deficiency disease.
Evolve announced dosing the first pediatric patient in its Phase III trial for PlasmaCap IG, an IVIG therapy.
Overview of PlasmaCap EBA technology, which captures plasma proteins in their native form with higher efficiency and selectivity.
Evolve Biologics announced the appointment of Chris Carr as Chief Financial Officer, responsible for finance and accounting functions.
Evolve Biologics announced the site selection, land purchase, and groundbreaking ceremony for its first manufacturing facility in Sachse, Texas, which will use PlasmaCap EBA® technology.
Evolve announced the selection of DPR Construction as the general contractor for its first manufacturing facility in Texas, which will utilize PlasmaCap EBA® technology.
Evolve announced the successful completion of Phase III clinical trials for PlasmaCap IG, an intravenous immunoglobulin therapy for primary immune deficiency disease.
Evolve announced dosing the first pediatric patient in its Phase III trial for PlasmaCap IG, an IVIG therapy.
Overview of PlasmaCap EBA technology, which captures plasma proteins in their native form with higher efficiency and selectivity.